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Abstract 
Background: Sub‑lethal doses of ionizing radiation (IR) can alter the phenotype of target tissue by modulating genes 
that influence effector T cell activity. Previous studies indicate that cancer cells respond to radiation by up‑regulating 
surface expression of death receptors, cell adhesion molecules and tumor‑associated antigens (TAA). However, there 
is limited information available regarding how T cells themselves are altered following these interactions with irradi‑
ated tumor cells.
Methods: Here, several human colorectal tumor cell lines were exposed to radiation (0–10 Gy) in vitro and changes 
in the expression of molecules costimulatory to effector T cells (4‑1BBL, OX‑40L, CD70, ICOSL) were examined by flow 
cytometry. T cell effector function was assessed to determine if changes in these proteins were directly related to the 
changes in T cell function.
Results: We found OX‑40L and 4‑1BBL to be the most consistently upregulated proteins on the surface of colorectal 
tumor cells post‑IR while ICOSL and CD70 remained largely unaltered. Expression of these gene products correlated 
with enhanced killing of irradiated human colorectal tumor cells by TAA‑specific T‑cells. Importantly, blocking of both 
OX‑40L and 4‑1BBL reversed radiation‑enhanced T‑cell killing of human tumor targets as well as T‑cell survival and 
activation.
Conclusions: Overall, results of this study suggest that, beyond simply rendering tumor cells more sensitive to 
immune attack, radiation can be used to specifically modulate expression of genes that directly stimulate effector T 
cell activity.
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Background
Radiotherapy (RT) is an extremely common modality in 
cancer treatment. Many cancer patients undergo RT dur-
ing their course of illness however tumor cells acquire 
mutations during development that inhibit cell death by 
radiation [1]. RT also fails to control systemic disease and 
many cancer patients experience disease recurrence [2]. 
Moreover, radiation has significant dose limiting toxici-
ties when used as a definitive therapy or in sensitive tis-
sues such as the colon [3, 4]. Cancer immunotherapy 
(CIT) is emerging as an attractive therapeutic option and 
many standard cancer therapies, such as chemotherapy 
and radiation, rely on induction of functional immune 
cells for efficacy [5, 6]. Indeed, combination CIT and RT 
is more effective in treating metastatic and reoccurring 
cancers than either of the therapies alone [7–15]. Fully 
understanding the role of RT in tumor immunity will 
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have a major impact on the treatment of cancers combin-
ing these modalities [16].
Effective cancer immunotherapy (CIT) strategies aim 
to generate tumor-specific CD8+ CTLs to attack and 
kill tumor cells [17, 18]. To elicit an effective immune 
response against tumors, the immune system needs to 
recognize tumor-associated antigen (TAA) presented to 
the TCR within MHC Class-I molecules, in conjunction 
with appropriate co-stimulation [19, 20]. Most cancer 
patients have some level of TAA-specific T cells. Sur-
prisingly, treatments that further induce or expand the 
number of anti-TAA CTLs do not consistently translate 
into objective clinical tumor responses. As such, it is 
clear that that increasing tumor-specific CTL numbers 
is insufficient to control malignant cells and eliminate 
cancer. Several possibilities for this outcome include 
weak immunogenicity of TAA, low expression of co-
stimulatory molecules on tumor cells and APCs, and/or 
secretion of suppressive molecules or recruitment of sup-
pressive cells.
Local tumor irradiation has been shown to generate 
tumor-specific CTL and enhance anti-tumor immune 
responses [21–25]. Sub-lethal doses of ionizing radia-
tion (IR), for example, have been reported to up-regulate 
expression of immune-stimulatory proteins in various 
tissue types both in vitro and in vivo [25, 26]. We previ-
ously reported that exposure of human carcinoma cell 
lines to sub-lethal radiation results in enhanced suscep-
tibility to lysis by tumor specific cytotoxic T cells (CTLs) 
[26, 27]. Significantly enhanced killing by CEA-specific 
CD8+ CTLs was observed in five of five colorectal car-
cinoma (CRC) cell lines exposed to a single dose of 10 Gy 
radiation. Furthermore, enhanced attack by CTLs in head 
and neck squamous cell carcinoma [27] and prostate 
carcinoma [28] suggests the functional enhancement is 
not limited to a single antigen-specificity or cancer type. 
More recently we reported that irradiation of human 
tumor cells imparts enhanced and sustained susceptibil-
ity to multiple death receptor signaling pathways [29]; 
however, the differences in magnitude of lysis among 
the cell lines does not correlate with altered expression 
of death receptors, nor altered surface expression of 
MHC-I, ICAM-1 or TAAs [26]. Thus, the mechanism 
of enhanced CTL killing against human carcinoma cells 
is unclear and surprisingly few studies focus on under-
standing the effect of radiation-induced changes in tumor 
cells on CTL effector activity and function.
Tumor derived antigens often induce insufficient co-
stimulation and induce immune tolerance to the antigen. 
Antigen presentation in a toleragenic or immunosup-
pressive environment where robust costimulation is not 
present leads to sub-optimal immune responses such as 
T-cell anergy. T-cell co-stimulatory agonists can program 
T cells encountering these non-immunogenic antigens to 
expand and develop anti-tumor effector activities [30]. 
As a result, strategies for improving positive co-stimu-
lation to T cells and reversing negative regulation of T 
cells are currently very attractive therapeutic approaches 
for cancer therapy. The latter approach has resulted in 
recent FDA approval of several T cell checkpoint block-
ade agents. Regarding positive signals to T cell, the co-
stimulatory molecules 4-1BB ligand (4-1BBL/TNFSF9/
CD137L) and OX-40 ligand (OX-40L/TNFSF4/CD134L/
CD252) are important regulators of CTL function, and 
lack of signaling through these molecules results in 
reduced CTL activity [20, 31–33]. In tumor bearing mice, 
intratumoral OX-40 activation increases CD40 expres-
sion on T cells and increases the effector memory T cells 
(TEM) subset [34]. 4-1BBL (TNFRSF9/CD137) costimu-
lation of tumor-specific T cells is important for T-cell 
activation and 4-1BBL transfected DCs elicit more effec-
tive responses and enhanced CTL killing of tumor cells, 
due to increased expression of perforin and IFN-γ [35]. 
In recognition of the importance of these pathways to 
generating effective antitumor immunity, clinical studies 
have started to evaluate the effectiveness of humanized 
agonist antibodies to both OX-40 and 4-1BB [36–39]. 
Engagement of OX-40 and 4-1BB by agonist (activating) 
antibodies increases tumor immunity, resulting in long-
term survival in a number of murine tumor models [32, 
40–42]. These costimulatory signals may be particularly 
important for effective responses against self-antigen 
such as those expressed by many tumor cells. In the 
absence of these co-stimulatory signals anti-tumor effec-
tor T-cells may be rendered anergic.
Our previous studies suggest that sub-lethal doses 
of radiation cause altered expression of genes within 
tumor cells resulting in increased CTL-mediated lysis 
[26]. More recently, we reported that radiation increased 
expression both OX-40L and 4-1BBL in human pros-
tate cancer cells [43], and that increased expression of 
4-1BBL in colorectal tumor cells occurred via epigenetic 
changes at the promoter [44]. The present study was 
designed to test the hypothesis that enhanced activity of 
TAA-specific CTLs against tumor cells surviving radia-
tion is mediated, in part, through increased effector co-
stimulation from OX-40L and 4-1BBL on tumor cells. To 
our knowledge, this is the first study to (a) demonstrate 
that radiation specifically modulates OX-40L and 4-1BBL 
expression while leaving expression of other co-stimula-
tory molecules such as CD70 and ICOSL unchanged, (b) 
report OX-40L and 4-1BBL expression upregulated in a 
panel of colorectal cancer cell lines post-IR, (c) show that 
irradiated tumor cells that do not increase co-stimulatory 
molecule expression also do not increase T cell activity, 
and (d) determine that CTL killing of irradiated tumor 
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cells is abolished in the presence of a neutralizing anti-
body against OX-40L and silenced 4-1BBL expression. 
Overall, the results of this study suggest that tumors sur-
viving radiation therapy are not simply rendered more 
‘sensitive to T cells attack’ but actively modulate expres-




Human colorectal carcinoma cell lines HCT116, Caco-2 
and WiDr, were obtained from the laboratory of tumor 
immunology and biology, LTIB, NCI, NIH. SW620, 
HT-29, LS174T and Colo205 cells were purchased 
from ATCC. All cells were cultured as recommended 
by ATCC and tested periodically to ensure absence of 
Mycoplasma. Cells were incubated at 37  °C incubator 
with 5  % CO2. The use of these de-identified and com-
mercially purchased cell lines received exempt approval 
under a human investigation protocol approved by the 
Institutional Review Board of Georgia State University 
(#H13305).
Irradiation
A RS-2000 biological X-ray irradiator (Rad source tech-
nology, Suwanee, GA) was used to irradiate tumor cells. 
Cells were irradiated at a dose rate of 2 Gy/min at volt-
age and current of 160 kV and 25 mA, respectively. Cells 
were maintained in suspension and kept on ice during 
irradiation. Immediately after irradiation, cells were cen-
trifuged and cells were plated in tissue culture plates in 
fresh media.
RNA isolation
At 24 or 48  h post-IR, RNA was extracted from tumor 
cells using RNeasy mini kit (Qiagen Inc. Valencia, CA) 
according to manufacturer’s instructions. Purified RNA 
was DNase-treated by Rnase-free DNase (Qiagen Inc. 
Valencia, CA) following manufacturer’s instructions.
Flow cytometry
Cells were stained with species-specific primary labeled 
mAb [CD137L (4-1BBL)-PE, CD252 (OX-40L)-PE, 
CD70-FITC, ICOSL-PE, CD8α-FITC, CD107a-APC, 
CD25-APC, CD69-PE, CD66-PE, CD227 (MUC-1)-
FITC] purchased from BioLegend or BD biosciences (San 
Diego, CA). Surface staining was done in cell staining 
buffer for 30 min on ice. 7AAD dye were obtained from 
BD biosciences (San Diego, CA) and used according to 
manufacturers instructions to measure cell death. Intra-
cellular staining of active caspase-3 was done accord-
ing to manufacturer’s instruction. Flow cytometry data 
were acquired on BD Fortessa and analyzed with FlowJo 
software (TreeStar). The live cells population was gated 
on the FSC and SSC scatter plots for analysis of surface 
proteins. No live cells gate was used for cell death analy-
sis samples. Samples were stained with the appropriate 
isotype control antibodies and gates were set to less than 
5 % in all isotype control samples.
Generation of cytotoxic T‑lymphocytes
Cell-rich leukapheresis collections from HLA-A2+ 
donors were obtained from Hemacare (Van Nuys, CA), 
with appropriate informed consent, for generating anti-
gen specific CTLs as previously described [27, 45, 46]. 
These commercially purchased (and de-identified) tis-
sues received exempt approval under a human investiga-
tion protocol approved by the Institutional Review Board 
of Georgia State University (#H13305). Briefly, PMBCs 
that adhered to the tissue culture flask after 2 h were cul-
tured for 7  days in AIM-V media (Invitrogen) contain-
ing 100 ng/ml of human granulocyte colony stimulating 
factor (GM-CSF) and 20 ng/ml of IL-4 (Miltenyi Biotec, 
Inc. Auburn, CA). On the fifth day in culture 500  ng/
ml CD40L (Millipore corporation, Temecula, CA) was 
added to mature the DCs. Matured DCs were then col-
lected and loaded with 40  μg/mL of HLA-A2 binding 
peptides. CEA peptide (YLSGANLNL (CAP-1; [46]) or 
MUC (ALWGQDVTSV) peptides were allowed to bind 
to the DCs for 4 h in a 37 °C 5 % CO2 incubator. and sub-
sequently irradiated with 50 Gy. Immunomagnetic beads 
(Miltenyi Biotec Inc. Auburn, CA) were used to isolate 
CD8+ T cells from the non-adherent fraction of PBMCs. 
The peptide pulsed DCs were used to stimulate CD8+ 
T cells in media containing 10 ng/ml of IL-7 (Millipore, 
Temecula, CA). After 3  days in culture 30U/ml of IL2 
(Millipore, Temecula, CA) were added. T-cells were res-
timulated in this manner weekly using autologous anti-
gen presenting cells. On the fourth day of stimulation T 
cells were isolated and used in a standard cytotoxic kill-
ing assay.
Cytotoxicity assay
CTL lysis of HCT116, SW620, Colo205, and LS174T 
(HLA-A2-) tumor cells was measured using the DELFIA 
cell cytotoxicity kit (Perkin Elmer). Seventy two hour 
after irradiation, viable and proliferating tumor cells 
(2 ×  106/2  ml) were harvested, counted, and incubated 
with 5 μl of BATDA (bis (acetoxymethyl) 2,2′:6′,2′′- ter-
pyridine- 6,6′′- dicarboxylate; PerkinElmer, Boston, MA) 
for 20 min at 37 °C. After incubation, cells were washed 
four times with PBS. 5 ×  103 cells were added in tripli-
cate to a 96-well U-bottom plate, and either CEA or 
MUC specific CD8+ T-cell were added to the wells (E:T 
ratios between 12:1 and 30:1) and incubated for 4–5 h at 
37  °C. After incubation, the plate was centrifuged (500g 
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for 5 min) and 20 μl of supernatant were transferred into 
a flat bottom plate. Two hundred microlitre of Europium 
solution was added and incubated for 15  min at room 
temperature on plate shaker [47]. Lysis was measured 
on a time resolved Victor3 plate reader fluorometer. The 
percentage of tumor lysis was calculated as follows:   % 
tumor lysis = experimental release (counts) − spontane-
ous release (counts)/maximum release (counts) − spon-
taneous release (counts) × 100.
Expression knock‑down and blocking
4-1BBL gene expression was knocked down using a 
gene specific siRNA. Briefly, tumor cells were plated in a 
6-well dish at 1 × 105 cells/well 1 day prior to transfec-
tion, with 50–70 % confluence on the day of transfection. 
In some experiments 2 × 104 cells were plated in 24-well 
plates. 4-1BBL Flexi Tube siRNA #6 (Qiagen Inc. Valen-
cia, CA) was diluted in optiMEM medium (invitrogen) 
and transfected using Hyperfect (Qiagen Inc. Valencia, 
CA). Twenty-four hours post transfection; cells were 
irradiated with 10 Gy or mock-irradiated. The cells were 
harvested 24–48  h post irradiation and 4-1BBL mRNA 
expression was measured. A negative control siRNA that 
was not specific to 4-1BBL was also transfected into cells 
and 4-1BBL mRNA similarly evaluated. Using combina-
tion 4-1BBL and OX-40L siRNA to knock down both 
genes simultaneously resulted in incomplete knock-down 
of both genes in our tumor cells. As a result, for dual 
blockade experiments, we knocked down 4-1BBL using 
siRNA and we used a Goat anti-human OX-40L-neutral-
izing antibody (R&D system, Minneapolis, MN) to block 
OX-40 ligand and receptor interaction (cat #: AF1054). In 
the indicated groups, 500 ng/ml of anti-human OX-40L 
neutralizing antibody was added to Eu-labeled tumor 
cells for 15  min prior to adding TAA-specific CTLs. 
The anti–human 4-1BB monoclonal blocking antibody 
BBK-2 [48] was added 20  μg/ml 15  min before T-cells 
were added. Isotype matched antibodies were added to 
the other groups as a negative control. In parallel experi-
ments, the percent of T cells expressing CD25 (activa-
tion) or positive for active Caspase-3 (cell death) was 
measured by flow-cytometry as previously described 
[44].
Statistical analysis
Statistical difference in the distribution of flow cytomet-
ric data from several repeat experiments were graphed 
and the mean of three to four independent experiments 
were calculated and an un-paired two-tailed student 
T-test was performed using Graphpad by Prism. Statis-
tical differences between groups in the cytolysis assays, 
activation, and survival assays were calculated using 
un-paired one or two-tailed student T-test and calculated 
for the 95 % confidence interval (CI).
Results and discussion
Sub‑lethal irradiation of colorectal carcinoma cell lines 
does not modulate all T cell stimulatory molecules the 
same
There are a number of proteins that, when expressed 
by target cells, can contribute to enhanced local activ-
ity of CD8+ cytolytic T cells through increased activa-
tion or survival. Signals transduced by proteins such as 
4-1BB, OX-40, CD27 and ICOS are regarded as especially 
important for survival, expansion and effector function 
of T cells that have initially received activating signals 
via the CD28 receptor [31, 32]. We previously reported 
increased expression of OX-40L and 4-1BBL in two colo-
rectal tumor cell lines [44] and wanted to evaluate if the 
expression of other co-stimulators of CD8+ effector cells 
was also changed in irradiated colorectal tumor cells. For 
this we extended our evaluation to another TNFSF mem-
ber, CD70 (CD27L/TNFSF7), and to a B7-related protein 
family member, ICOSL (CD275/B7-H2), and included 
three additional human colorectal cell lines (WiDr, 
HT-29 and Colo205). No increase in either CD70 (Fig. 1a) 
or ICOSL (Fig. 1b) was detected in HCT116 cells treated 
with 10 Gy of radiation. This is in contrast to the increase 
in 4-1BBL detected in the same cells post-IR (Fig.  1c). 
We also detected no increase in CD70 in any of the colo-
rectal tumor cell lines evaluated (Fig.  1d). Furthermore, 
while we saw an increase in ICOSL expression in SW620 
cells (0.2 %–0 Gy versus 14.10 %–10 Gy), we were unable 
to see a change in ICOSL expression in any of the other 
tumor cell lines evaluated. In addition, no increase in the 
expression of B7-1 (CD80) was observed following irra-
diation in any of the cell lines evaluated (data not shown). 
These data suggest that not all T cell costimulatory mol-
ecules are modulated post-IR and that the modulation of 
OX-40L and 4-1BBL may be selectively altered following 
radiation therapy of colorectal tumor cells.
Sub‑lethal irradiation of most human colorectal carcinoma 
cell lines enhances OX‑40L and 4‑1BBL expression
To further investigate if the ability of radiation to modu-
late OX-40L and 4-1BBL was common among colorec-
tal tumor cells we expanded our examination of OX-40L 
and 4-1BBL expression to a larger panel of human colo-
rectal tumor cell lines (HCT116, SW620, HT-29, Caco-
2, Colo205 and WiDr). Cells were irradiated, and the 
surface expression of these proteins was evaluated by 
flow cytometry after 48–72  h. We observed 18.8  % of 
non-irradiated WiDr cells expressed OX-40L, and this 
increased to 20.9  % following 5  Gy, and 61  % following 
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10 Gy (Fig. 2a). The average of three replicate experiments 
in WiDr cells revealed an average increase in expression 
of 44  % following radiation from 17  % in cells receiving 
no radiation (P =  0.0295). As reported previously, there 
was a significant increase in OX-40L expression in both 
HCT116 and SW620 (Fig.  2b) [44]. Though radiation 
increased the expression of OX-40L in HT-29 and Caco-2 
cells repeatedly, it was not significant based on the aver-
age of replicate experiments and there was no increase in 
expression observed in Colo205. Staining of cells with iso-
type control antibody was below 5 % in all cells evaluated 
(data not shown). We next evaluated the surface expres-
sion of 4-1BBL in the same colorectal tumor cell lines. 
Figure  3a shows the level of 4-1BBL protein on the sur-
face of untreated WiDr cells (1.17 %). The level of 4-1BBL 
increases following both 5 Gy (11.5 %) and 10 Gy (40.2 %) 
treatment. The average of three replicate experiments 
revealed a significant increase in expression from 4  % 
(0 Gy) up to 33 % following 10 Gy irradiation of WiDr cells 
(P = 0.0013). Expression of 4-1BBL also increased in four 
of the five other tumor cell lines tested (Fig. 3b) and this 
increase was significant in SW620, HCT116 and Caco-2 
cells. Again, Colo205 cells were the exception and radia-
tion did not increase the expression of 4-1BBL. We also 
evaluated the longevity of increased OX-40L and 4-1BBL 
and found that the elevated expression of 4-1BBL protein 
could still be seen 7 days post-IR in WiDr, HCT116 and 
SW620 cells, and the elevated expression of OX-40L was 
maintained in WiDr cells but not in SW620 cells (data not 
shown). These data suggest that expression of these pro-
teins is modulated in most colorectal tumor cell lines by 
radiation, and the change can be sustained in some cases.
Fig. 1 Expression of CD70 and ICOSL following tumor cell irradiation. a CD70 expression (black line). b ICOSL expression (black line). c 4‑1BBL 
expression (black line) 48 post‑IR in HCT116 cells. Isotype control stained cells were all less than 5 % positive (filled grey histogram). d CD70 and ICOSL 
expression in treated and untreated SW620, WiDr, HT‑29 and Colo205 cells. Experiments repeated two and three times with similar results
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Sub‑lethal irradiation increases CEA and MUC‑specific 
cytotoxic T‑cell mediated killing of HCT116 and SW620 
cells, but not of Colo205 cells
Both HCT116 and SW620 cells are killed better post-
IR by TAA-specific CTLs [26] and while both modulate 
surface expression of death receptors post-IR, SW620 
cells have a non-functional Fas pathway while HCT116 
cells are sensitive to killing through this pathway [29]. 
Both cells lines do, however, increase expression of OX-
40L and 4-1BBL post-IR (in contrast to Colo205 cells 
which do not modulate either protein) (Figs.  2 and 3). 
We wanted to determine if increased killing could be 
observed against tumor cells that do not modulate the 
positive costimulatory molecules (Colo205), and further, 
to evaluate if enhanced killing occurred if a lower dose of 
radiation (5 Gy) was used. Human colorectal tumor cell 
lines HCT116, SW620 and Colo205 were irradiated with 
a single dose of 0, 5 or 10 Gy radiation. Following tumor 
cell irradiation only adherent and proliferating cells were 
harvested. We have previously demonstrated that tumor 
cells remain viable and continue to proliferate using this 
method [29]. At 72 h post-IR, tumor cells were evaluated 
in a 4 h Europium-release cell cytotoxicity assay [47] with 
CEA-specific CTLs. Similar to our previous observa-
tions, 10 Gy irradiated SW620 and HCT116 tumor cells 
were killed significantly better by CEA-specific CTLs 
when compared to non-irradiated tumor cells (Fig.  4a). 
Tumor cell lysis by CTLs could also be observed in tumor 
cells receiving as low as 5 Gy of radiation (17.9 % lysis of 
SW620 and 5  % lysis of HCT116). To evaluate if CTLs 
that were specific to another TAA expressed in these 
colorectal tumor cells would demonstrate enhanced kill-
ing of irradiated tumor targets we evaluated cytotoxic 
activity of mucin-1 (MUC1) specific cytotoxic T cells. 
MUC-specific CTLs did not lyse non-irradiated SW620 
cells, however lysis increased to 32.7 and 44.1 % if tumor 
cells received 5 Gy (P = 0.0278) or 10 Gy (P = 0.0013) of 
radiation, respectively (Fig. 4b). Here, both HCT116 cells 
and SW620 tumor cells displayed significantly enhanced 
killing by MUC specific CTLs after irradiation with 
10  Gy (p  =  0.015 HCT116), and again killing could be 
observed when 5  Gy of radiation was used. Thus, these 
data suggest that tumor cells surviving irradiation are 
more susceptible to cytotoxic T-cell killing by T cells of 
diverse antigen specificity and at doses lower than the 
previously reported 10  Gy. In contrast to the killing of 
Fig. 2 Tumor cells modulate OX‑40L protein expression after treatment with radiation. a Irradiated (5 and 10 Gy) and non‑irradiated (0 Gy) WiDr 
colorectal carcinoma cells were stained with PE‑labeled antibody to human OX‑40L. Isotype control staining is shown in gray filled histogram. 
OX‑40L‑PE positive cells are shown in solid black line histogram. b OX‑40L expression in five additional tumor cell lines receiving 10 Gy (black bar) or 
0 Gy (gray bar). *P value <0.05. Data graphed are the mean of two (Caco2), three (HCT116, Colo205, HT‑29) or four (SW620) experimental repeats and 
error bars represent the SEM across the independent experiments
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SW620 and HCT116 tumor cells, the percent lysis by 
both CEA-specific and MUC-specific T-cells was below 
10 % after irradiation of Colo205 cells and untreated cells 
were also not killed (Fig.  4c). Thus, tumor cells that do 
not modulate OX-40L or 4-1BBL post-IR were also not 
killed by TAA-specific CTLs post-IR. As a negative con-
trol, lysis of MHC-mismatched colorectal tumor cells 
LS174T (CEA + MUC +/HLA-A2−) was less than 5 % 
at all doses of radiation in the same assay even though 
both CEA and MUC expression was increased (Fig. 4d). 
Furthermore, we observed similar enhancement of T cell 
survival and activation. Irradiated HCT116 and SW620 
cells increased T cell survival and activation while 
Colo205 cells did not (data not shown).
Though HCT116 and SW620 cells modulate OX-40L 
and 4-1BBL post-IR and Colo205 cells do not, it is unclear 
what is responsible for the variable magnitude of cytoly-
sis among the cell lines examined. These differences, 
however, do not appear to correlate with altered sur-
face expression patterns of MHC-I or TAA. Specifically, 
HCT116 cells are killed post-IR while Colo205 cells are 
not (Fig. 4a, c). This occurs despite the fact that Colo205 
cells express more MHC molecules per cell than HCT116 
cells, as determined by both mean fluorescence intensity 
(MFI) (255 vs 226 respectively) and percent positive cells 
(74.6 vs 99.5 %) (Fig. 4e). SW620 and HCT116 cells dem-
onstrate similarly enhanced cytolysis by CEA-specific 
CTLs post-IR (Fig. 4a). SW620 cells express more MHC-I 
(MFI 302) than HCT116, however, they actually decrease 
the amount of surface CEA (93 vs 85.3  %). All four cell 
lines were greater than 95 % positive for Pan MHC class I 
detected using and HLA-ABC antibody (data not shown), 
however LS174T were less than 5 % positive for HLA-A2. 
Though the impact of radiation on antigen processing 
and presentation remains under study, increased anti-
gen presentation in a toleragenic or immunosuppressive 
environment where robust costimulation is not present 
could still lead to sub-optimal immune responses.
4‑1BBL and OX‑40L dual co‑stimulation is required 
for radiation‑enhanced sensitivity to CTL killing
In addition to delivering anti-apoptotic signals to T cells, 
OX-40 and 4-1BB signaling have been reported to pro-
gram effector function in T cells [49–54], and result in 
Fig. 3 Tumor cells modulate 4‑1BBL protein expression after treatment with radiation. a Irradiated (5 and 10 Gy) and non‑irradiated (0 Gy) WiDr 
colorectal carcinoma cells were cultured and subsequently stained with PE‑labeled antibody to 4‑1BBL. Isotype control staining is shown in gray 
filled histogram. 4‑1BBL‑PE positive cells are shown in solid black line histogram. b 4‑1BBL expression in five additional colorectal tumor cells lines 
receiving 10 Gy (black bar) or 0 Gy (gray bar). *P value <0.05. Data graphed are the mean of three (Colo205, HT‑29, Caco2) or four (HCT116, SW620) 
experimental repeats and error bars represent the SEM across the independent experiments
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effective anti-tumor immunity. These data indicate that 
T-cell effector function can be enhanced through co-
stimulation of these pathways. Indeed, in the present 
study we detected no change in the expression of OX-
40L or 4-1BBL in Colo205 cells (Figs.  2b and 3b) and, 
interestingly, these cells also showed no enhancement of 
CTL killing post-IR (Fig.  4c). These results suggest that 
the enhanced CTL killing of irradiated tumor cells may 
be due to the enhanced expression of the co-stimulatory 
molecules OX-40L and 4-1BBL. To further investigate 
whether OX-40L and 4-1BBL are involved in enhanced 
CTL killing of irradiated colorectal tumor cells, we per-
formed CTL cytotoxicity assays after blocking and/
or inhibiting these molecules. For these experiments, 
the ligand-receptor interaction of OX-40/OX-40L was 
blocked using neutralizing antibody against human OX-
40L, and radiation-induced 4-1BBL was knocked down 
in tumor cells using homologous siRNA. We observed 
elimination of the radiation-induced increase in 4-1BBL 
mRNA in SW620 cells transfected with 4-1BBL-specific 
siRNA but not negative control siRNA (Fig. 5a). We next 
measured the CTL-mediated killing in tumor cells in 
which either 4-1BBL was knocked down using siRNA or 
wherein OX-40L signals were blocked using a neutral-
izing ab. As expected, 10 Gy of radiation enhanced CTL 
lysis in SW620 cells (Fig.  5b; black bars). SW620 cells 
displayed a reduction in CTL killing when either 4-1BBL 
(P = 0.0724) was knocked down by siRNA (Fig. 5b; dark 
gray bar) or OX-40L (P =  0.0379) signals were blocked 
using neutralizing antibody (Fig. 5b; light gray bar), and 
this was further reduced to levels similar to untreated 
control cells when both signals were blocked (checked 
bar, P = 0.0316) (Fig. 5b; checked bar). CTL cytolysis of 
irradiated SW620 cells was also inhibited if 4-1BB signals 
were blocked using a neutralizing antibody to 4-1BB (on 
the T-cell) in combination with the OX-40L neutraliz-
ing antibody (data not shown). Furthermore, radiation-
induced activation of CD8+ CTLs, as determined by 
CD25 expression, was reversed when dual blockade was 
performed (Fig. 5c). Forty eight hours after cytolysis assay 
Fig. 4 Sensitivity to CEA‑ and MUC‑specific T‑cell mediated cytolysis in irradiated colorectal tumor cells. a HLA‑A2 positive HCT116 and SW620 
cells treated in vitro with 0 Gy (white bar), 5 Gy (gray bar) or 10 Gy (black bar) of ionizing radiation were used as targets in a 4 h CTL cytolysis assay. At 
72 h post‑IR, HLA‑A2 restricted CEA‑specific T cells were used as effector cells at an E:T of 25:1. b Irradiated (5 and 10 Gy) and non‑irradiated (0 Gy) 
HCT116 and SW620 cells were used in a 4 h lysis assays with MUC‑specific T cells. At 72 h post‑IR, MUC‑specific T cells were used as effector cells 
at an E:T of 25:1 (HCT116) or 12:1 (SW620). c HLA‑A2 positive colo205 cells were used in a cytolysis assay with either CEA‑specific or MUC‑specific 
T cells at an E:T of 30:1. d HLA‑A2 negative LS174T cells were used in a cytolysis assay with either CEA‑specific or MUC‑specific T cells at an E:T of 
30:1.*P value <0.05. Error bars indicate variability in technical replicates. Experiments were repeated at least three times with similar results. e Irradi‑
ated (10 Gy) and non‑irradiated (0 Gy) CRC cells were cultured and subsequently stained with PE‑labeled antibodies for flow cytometry to measure 
surface expression of HLA‑A2 and TAA proteins on the surface of colorectal tumor cells. Isotype control staining of irradiated cells was less than 5 % 
positive. Numbers indicate  % of cells positive and those in parenthesis indicate mean fluorescence intensity (MFI) of cells expressing molecule on 
the cell surface 72 h post‑irradiation. (dashed line) indicates level of detection below background. CEA carcinoembryonic antigen, MUC Mucin‑1
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set-up 17.6 % of CD8+ cells expressed CD25 when incu-
bated with irradiated SW620 cells as compared to 12.6 % 
of CD8+ cells following interaction with non-irradiated 
SW620 cells. When both 4-1BBL and OX-40L signals 
were absent only 13.8 % of CD8+ cells expressed CD25. 
As a positive control, CD25 expression was detected on 
84 % of T-cells stimulated with phorbol myristate acetate 
(PMA) and ionomycin. Data from several independ-
ent experiments (Fig.  5d) depict significant changes in 
CD25 expression between untreated and 10  Gy treated 
cells (P =  0.002) as well as between 10  Gy-treated cells 
and 10 Gy-treated cells in the presence of dual blockade 
(P  =  0.04). These data suggest that T cells exposed to 
irradiated tumor cells have improved activation. We per-
formed similar evaluation of HCT116 cells to determine 
if these results could be observed in another colorectal 
tumor cell line. 4-1BBL mRNA was significantly reduced 
in cells treated with the 4-1BBL siRNA as compared to 
cells treated with the negative control siRNA (Fig.  6a). 
The enhanced cytolysis observed after irradiation with 
10  Gy was reduced when both 4-1BBL was knocked 
down and the OX-40L blocking antibody were used in 
combination (P  =  0.067) (Fig.  6b). Overall, these data 
suggest that radiation-enhanced tumoricidal activity of 
Fig. 5 Radiation‑enhanced sensitivity to T‑cell mediated lysis and T‑cell activation is reduced in the absence of OX‑40L and 4‑1BBL. a 4‑1BBL was 
knocked down in tumor cells as described in “Methods” section. Briefly, 1 × 105 SW620 cells were and transfected the following day with 4‑1BBL 
siRNA or a control siRNA. 24 h post‑transfection, the cells were irradiated with 10 Gy. Forty‑eight hours post‑IR, cells were harvested and 4‑1BBL 
mRNA was quantified. *P value <0.05. Data graphed are the mean of two experimental repeats and error bars represent the SEM across the inde‑
pendent experiments. b 2 × 104 SW620 cells were plated in 24‑well plates and transfected with 4‑1BBL siRNA or a control siRNA. After transfection, 
the cells were irradiated with 10 Gy. Forty‑eight hour post‑IR cells were used in a Eu‑release cytotoxicity assay using CEA‑specific T‑cells at an E:T 
ration of 30:1. In the indicated groups, neutralizing antibody to human OX‑40L was added to SW620 cells used in the cytolysis assay. *P value <0.05. 
Error bars indicate variability in technical replicates. Experiments repeated at least two times with similar results. c Forty‑eight hour after cytolysis 
assay set‑up, cells were harvested and stained for markers of T‑cell activation. Flow cytometry plots showing the frequency of CD25+ cells within 
the CD8+ cell population after incubation with irradiated SW620 cells. d Data from three independent experiments is shown graphically and error 
bars represent the SEM across the independent experiments. *P value <0.05 between untreated versus 10 Gy treated or 10 Gy treated versus dual 
blockade
Page 10 of 14Kumari and Garnett‑Benson  BMC Res Notes  (2016) 9:92 
CTLs could be due, in part, to enhanced expression of 
both OX-40L and 4-1BBL and increased T cell activa-
tion via increased CD25 expression (Fig. 5c). As a com-
ponent of the IL-2 receptor, CD25 it has been linked to 
increased survival and thus could be a contributor to the 
increased survival we observe following radiation treat-
ment of tumors [44]. To determine if blocking of OX-40L 
and 4-1BBL signaling could reverse radiation-enhanced 
T-cell survival we evaluated active Caspase-3 expression 
in T-cells co-incubated with HCT116 tumor cells for 
5 h. The flow cytometry data (Fig. 6c) are representative 
of three independent experiments with similar results 
and suggest that dual blockade on irradiated tumor cells 
increases the amount of T-cell death. We also evaluated 
the level of active caspase-3 in T-cells co-incubated with 
SW620 tumor cells for 18 h in blocking experiments. As 
before, we found active caspase-3 decrease from 31.5 % in 
untreated cultures down to 23.8 % in irradiated cultures. 
Active caspase-3 in T-cells was increased when both 
4-1BBL and OX-40L signals were blocked (26  %). Data 
from four independent experiments (Fig. 6d) depict sig-
nificant changes in the expression of Caspase 3 in T cells 
incubated with 10 Gy treated tumor cells as compared to 
both of the other groups (untreated and dual blockade). 
Overall, these data demonstrate that OX-40L and 4-1BBL 
signaling from irradiated tumor cells can enhance CTL 
tumoricidal activity and influence T-cell activation and 
survival.
Conclusions
There is a wide array of CIT strategies under clinical 
investigation in combination with RT for the treatment of 
advanced cancers. With the exception of studies using RT 
for lymphodepletion prior to adoptive cell transfer [55], 
most clinical investigations utilize RT as an adjuvant to 
immune-based therapies [13–15]. These studies demon-
strate enhanced immune responses, including expanded 
numbers of circulating anti-tumor CTLs and antibod-
ies in treated patients. Unfortunately, these increased 
immune responses have not translated to a significant 
reduction in tumor burden often enough [14, 56, 57] and 
the reasons for this unexpected lack of clinical response 
have yet to be resolved. Detailed investigation into the 
molecular mechanism that results in the ability of IR to 
enhance anti-tumor immune responses will be required 
to capitalize on these biological changes and allow for 
Fig. 6 Radiation‑enhanced T‑cell lytic activity and radiation‑enhanced T cell survival is reduced in the absence of OX‑40L and 4‑1BBL. a 4‑1BBL was 
knocked down in tumor cells as described in “Methods” section. Briefly, 1 × 105 HCT 116 cells were and transfected the following day with 4‑1BBL 
siRNA or a control siRNA. Twenty‑four hour post‑transfection, the cells were irradiated with 10 Gy. Twenty‑four hour post‑IR, cells were harvested 
and 4‑1BBL mRNA was quantified. *P value <0.05 and ** <0.0001. Data graphed are the mean of two experimental repeats and error bars represent 
the SEM across the independent experiments. b 2 × 104 HCT 116 cells were plated in 24‑well plates and transfected with 4‑1BBL siRNA or a control 
siRNA. After transfection, the cells were irradiated with 10 Gy and used the next day in a Eu‑release cytotoxicity assay as described in the “Methods” 
section. In the indicated group, neutralizing antibody to human OX‑40L was added to tumor cells used in the cytolysis assay. Error bars indicate vari‑
ability in technical replicates. Experiments repeated at least two times with similar results. c Flow cytometry histograms showing active Caspase‑3 
expression in T‑cells incubated alone or with treated HCT116 cells for 5 h. d The frequency of Caspase 3+ cells within the gated CD8+ population is 
shown. *P value <0.05 between incubation with 10 Gy‑treated tumor cells versus untreated or 10 Gy‑treated cells verus 10 Gy‑treated cells plus dual 
blockade. Line indicates the mean and error bars represent the SD across four independent experiments
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additional opportunities for eliminating advanced stage 
cancers. More recently, modulation of tumor cells by 
RT has come into the spotlight and it has become clear 
that cells surviving radiation have an altered phenotype 
that can be exploited by CIT approaches [43, 58, 59]. To 
our knowledge, our study reports for the first time that 
human colorectal cells surviving radiation modulate 
expression of both OX-40L and 4-1BBL, and that irra-
diated tumor cells promote CTL tumoricidal activity 
related to these changes.
Our previous CTL killing assays were done using CTLs 
against a single antigen specificity (CEA) and a single 
dose (10  Gy) [26]. In our current study, killing activ-
ity of both CEA-specific and MUC-specific T cells was 
enhanced, suggesting that radiation-enhanced lysis is 
not limited to a single antigen specificity or tumor cell 
line (Fig.  1). We also detected enhanced susceptibility 
to CTL killing in tumor cells treated with a lower dose 
(5 Gy) of radiation. We observed enhanced CTL activity 
against some tumor cells treated with radiation and won-
dered if other aspects of T-cell biology were differentially 
altered in tumor cells killed (HCT116 and SW620) ver-
sus not killed post-IR (Colo205). We reasoned that T cells 
capable of surviving longer after interacting with tumor 
cells would be more likely to have productive interac-
tions with tumor cells resulting in enhanced ability to kill 
tumor cells. Very few dead T cells were detected in cul-
tures of T cells alone; however, there was an increase in 
T-cell death upon incubation with untreated tumor cells 
(Fig. 6). Death of T-cells following interaction with tumor 
cells has been reported by others, and is thought to be 
caused by tumor expressed PDL1, FasL and/or activa-
tion induced cell death (AICD) [60–62]. Surprisingly, we 
detected a decrease in the number of dead T cells (Fig. 6) 
if the tumor cells had been treated with radiation as com-
pared to non-irradiated cells [44].
As both OX-40L and 4-1BBL have been reported to 
enhance T-cell survival and T-cell activation [38, 48, 
63, 64], we next evaluated their expression in a panel 
of tumor cells. We found that five of six CRC tumor 
cell lines increased surface expression of both OX-40L 
(Fig. 2), and 4-1BBL protein (Fig. 3) after treatment with 
10  Gy of ionizing radiation. Though non-treated tumor 
cells expressed variable amounts of both OX-40L and 
4-1BBL on their cells surface, this rarely exceeded 20  % 
in our experiments. Salih et al. (2000) measured 4-1BBL 
expression on carcinoma cells and found that HCT116 
cells expressed higher levels than HT-29 cells, which is in 
agreement with our observations in untreated tumor cells 
(Fig.  3b; gray bars). In contrast to OX-40L and 4-1BBL, 
radiation did not increase the expression of other co-
stimulatory molecules evaluated in this study, includ-
ing CD70, ICOSL and B7-1 (Fig.  1). The mechanism of 
selective gene expression is under continued investi-
gation, and data from our lab suggests that radiation is 
epigenetically regulating expression of 4-1BBL and OX-
40L [44]. Tumor cells irradiated in vitro may respond to 
radiation differently than tumors irradiated in vivo due to 
the influence of the microenvironment and validation of 
these changes in vivo is currently under study.
To determine if radiation-induced expression of OX-
40L and 4-1BBL plays a direct role in enhanced tumor 
cell susceptibility to lysis by CTLs, we conducted CTL 
cytolysis experiments in combination with molecu-
lar inhibition. We found that neither knocking down 
4-1BBL in tumor cells, nor inhibiting OX-40L signaling 
independently, completely reversed radiation-enhanced 
sensitivity to cytolysis (Fig.  5b). However, when both 
molecules were inhibited there was a more prominent 
loss of the radiation-enhanced killing of both SW620 and 
HCT116 cells by T cells (Figs.  5b and 6b), and reduced 
CD25 expression (Fig. 5c) and survival (Fig. 6c) of T cells. 
Both 4-1BBL and OX-40L signals have been reported by 
others to increase the production of effector molecules 
such as perforin and granzyme in stimulated CTLs [50, 
52]. Whether irradiated tumors are impacting produc-
tion or release of effector molecules from CTLs is cur-
rently under investigation. Ongoing mechanistic studies 
are evaluating which mechanism (increased survival or 
increased production/release of effector molecules or 
both) is primarily responsible for enhanced tumoricidal 
activity, as well as the relative contribution of each co-
stimulatory molecule following both in vivo and in vitro 
tumor cell irradiation. Others have recently reported that 
radiation increases antigen processing and presentation 
pathways within tumor cells [59]. Antigen processing 
and presentation were not directly assessed here, how-
ever, changes in MHC-I and TAA levels in the current 
study did not appear to noticeably align with the changes 
observed in T cell activities (Fig.  4e). Given the levels 
of TAA and HLA-A2 among the cells lines it is difficult 
to imagine SW620 and HCT116, but not Colo205 cells, 
enhance antigen processing and presentation of CEA 
and MUC-1 HLA-A2 restricted peptides. Particularly 
when Colo205 cells and HCT116 cells express compa-
rable amounts of CEA post-IR, and the frequency (99.5 
vs 74.6 %) of HLA-A2-expressing HCT116 cells actually 
decreases post-IR (Fig. 4e). While the impact of radiation 
on antigen processing and presentation in human tumor 
cells remains under worthwhile investigation, it remains 
likely that altered antigen presentation will work in con-
cert with other tumor changes.
The aims of this study were meant to provide data to 
support the growing use, and rationale application, of RT 
in combination with CIT. If IR-modulated expression of 
4-1BBL and OX-40L is shown to play a significant role 
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in the ability of RT to enhance effector CTL killing, this 
could be an alternative therapeutic approach to enhanc-
ing these important T-cell signals. This approach is par-
ticularly relevant given the severe toxicity that can occur 
when using agonistic antibodies. Furthermore, the use 
of agonist antibodies is not limited to tumor-specific 
T-cells and, as a result, non-tumor specific T cells can 
become activated and induce off-target effects. Using RT 
to induce these molecules, specifically on a focused tar-
get, represents a refinement in the approach by triggering 
these pathways in anti-tumor CTLs infiltrating irradiated 
tumors. Ongoing investigations include determining the 
impact of RT on tumor modulation in  vivo more com-
prehensively to assess the specificity of changes on tumor 
cells versus other cells in the microenvironment. We have 
previously reported on such “immunogenic modulation” 
(occurring in the absence of “immunogenic cell death”) 
following treatment of human tumor cells with docetaxel 
chemotherapy [65]. Utilization of such direct tumor cell 
to T-cell mechanisms from phenotypically altered tumor 
cells that do not die post-IR, in addition to enhanced 
“danger” signals from dying cells, should allow for syn-
ergy resulting in a more robust anti-tumor immune 
attack. Ultimately, if immunomodulation of tumor cells 
by IR is shown to have a profound and consistent effect 
on CTL activity this would provide support for using IR, 
along with CIT strategies, specifically to enhance signals 
to these cells and optimize anti-tumor CTL responses.
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